Back to User profile » Dr Matthew J Taylor
Papers published by Dr Matthew J Taylor:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Standard Gamble to Derive Utility Health States for Limbal Stem Cell Deficiency
Smith AB, Retzler J, Taylor MJ
ClinicoEconomics and Outcomes Research 2020, 12:535-546
Published Date: 15 September 2020
![Noteworthy comment: This study assessed different methods to determine whether high ICERs (incremental cost-effectiveness ratio) are caused by high drug costs, high ‘background costs’ or a combination of both and how different approaches can alter the impact of background costs on the ICER where the marginal cost-effectiveness ratio is close to, or above, the cost-effectiveness threshold.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology
Retzler J, Davies H, Jenks M, Kiff C, Taylor M
ClinicoEconomics and Outcomes Research 2019, 11:309-324
Published Date: 3 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of SQ® HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany
Green W, Kleine-Tebbe J, Klimek L, Hahn-Pedersen J, Nørgaard Andreasen J, Taylor M
ClinicoEconomics and Outcomes Research 2017, 9:77-84
Published Date: 16 February 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A
ClinicoEconomics and Outcomes Research 2014, 6:187-196
Published Date: 8 April 2014